Skip to content
MatchScript
Menu

Head-to-head · The Match Score

Found vs Invigor Medical

Both scored on the same six-factor Match Score. Found wins this matchup with a 88 to 85 edge.

Higher Match Score

Found

#2 · Grade B+

People who want the lowest price and behavior-change coaching bundled with medication.

Visit Found
VS

Invigor Medical

#10 · Grade B

Patients who want GLP-1 care alongside a wider wellness/hormone program.

Visit Invigor Medical

Factor by factor

The six sub-scores behind each Match Score. The quiz reweights these to your priorities — one provider can pull ahead for you on the factors you care about.

Budget Fit
96
82
Speed to Start
90
82
Formulary Match
80
82
Support Level
92
90
Flexibility
78
88
Transparency
90
84

Price, coverage & formulary

DetailFoundInvigor Medical
Semaglutide$129/mo$199/mo
Tirzepatide$129/mo$339/mo
CoverageAll 50 statesNot disclosed
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjectable onlyInjectable only
Match Score88 · B+85 · B
Winner: Found

Found edges out Invigor Medical, 88 to 85 on the default Match Score. A coaching-first program with aggressive, identical pricing on both molecules — the budget match to beat.

Invigor Medical is still a fair pick if its strengths line up with yours — best for: Patients who want GLP-1 care alongside a wider wellness/hormone program.

Worth a look either way: our overall #1 pick is CoreAge Rx (Match Score 91) — nationwide access, both molecules at one flat price, easy to cancel. Or take the 6-question quiz to see your personalized match.

Assume any provider we list may compensate us, at no cost to you. It never changes the Match Score.

Full Found reviewFull Invigor Medical review

More head-to-heads

Or browse alternatives to Found and all comparisons.

Pricing, states and verification reflect each provider's public disclosures at last review; the Match Score and its sub-scores are our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.